Saturday, October 3, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· February 24, 2026

AI-Enabled Edge and Autonomous Systems Take Center Stage

View original at globenewswire.com
AI-Enabled Edge and Autonomous Systems Take Center Stage AUSTIN, Texas, Feb…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • As an Army-sponsored vendor participating in TiC 2.0, we have a valuable opportunity to directly showcase NODE's unique ability to support Army units by providing our real-time explosive threat detection and mapping capabilities for soldiers on the ground

    80% confidence

  • We are especially excited to integrate our AI-powered detection data into the widely fielded GeoSuite platform, building a novel solution that can rapidly deliver greatly enhanced operational situational awareness to the teams taking part in this critical technology event

    80% confidence

  • Initial government revenue validates our technology platform and positions Safe Pro for continued operational expansion

    80% confidence

  • We believe global demand for AI-enabled drone intelligence and American defense technology is entering a sustained growth cycle

    80% confidence

  • The first quarter of 2026 represents a transformational period for Safe Pro

    80% confidence

  • Safe Pro believes it is entering a commercial and government adoption inflection point, transitioning from development-stage operations into scaling revenue generation and opportunities to access additional government programs

    80% confidence

  • Tactical edge AI enables faster reaction times and improves resilience in high-threat scenarios

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com